Dan's practice involves domestic and foreign patent prosecution primarily in the area of biotechnology, including the fields of cellular and molecular biology, oncology, immunology, microbiology, genetic engineering, biochemistry, pharmaceuticals, stem cells, RNAi, medical devices, and probiotics, among others.
Dan is experienced in drafting patent validity and infringement opinions, freedom-to-operate opinions, and due diligence evaluations of patent portfolios. He has worked with a broad range of clients, from small biotech start-ups to universities and established pharmaceutical companies. Dan has also authored and presented scientific publications in the fields of immunology, microbiology, parasitology, and ophthalmology.
Dan was a Technology Specialist then an Associate with Mintz Levin for several years before practicing as an Associate with another international law firm. Dan rejoined Mintz Levin in 2014.
Dan's doctoral dissertation focused on characterizing the pathogenic cascade of Acanthamoeba keratitis, a sight-threatening infection of the ocular surface. He was also the recipient of a doctoral training fellowship awarded by UT Southwestern and a grant-in-aid of research from the National Academy of Sciences, awarded by Sigma Xi, the Scientific Research Society.
Recognitions & Awards
• Best Legal Brief in the First Year Legal Practice Skills Program, Suffolk University
Professional & Community Involvement
• Member, Boston Bar Association
• Member, Boston Patent Law Association
• Member, Sigma Xi, the Scientific Research Society
• Co-author, Supreme Court Invalidates Biotech Method Patent in Mayo v. Prometheus, Intellectual Property Alert (03.26.2012)
• Co-author, Do You Qualify for the "Micro Entity" Discount?, Intellectual Property Alert (11.03.2011)